RecruitingNCT06581861

PREVENT ALL ALS Study

PREVENT ALL ALS - Longitudinal Biomarker Study for Participants Who Are Genetically at Risk for Amyotrophic Lateral Sclerosis (ALS)


Sponsor

St. Joseph's Hospital and Medical Center, Phoenix

Enrollment

600 participants

Start Date

Jul 25, 2024

Study Type

OBSERVATIONAL

Conditions

Summary

The ALL ALS Clinical Research Consortium is establishing research to collect a wide range of samples, clinical information and measurements from Amyotrophic Lateral Sclerosis (ALS) symptomatic, ALS gene carriers and control cohorts. This consortium is begin funded by the National Institutes of Health/National Institute of Neurological Disorders and Stroke (NIH/NINDS) and managed by two clinical coordinating centers (CCC) at Barrow Neurological Institute and Massachusetts General Hospital. The clinical sites are distributed across the country, and led by a group of collaborative principal investigators. Once data and samples are collected and harmonized, it will be made available to research community for future research into ALS and related neurological diseases. PREVENT protocol is specific for asymptomatic participants who are genetically at risk for ALS. The participants will be followed for up to 36 months (3 years), and will include 4 in-person on-site visits once a year and 6 off-site(remote) visits once in 4 months. The study includes collection of medical history, clinical outcomes, and blood samples once in 4 months. Additionally, the participants will complete patient reported outcomes and speech recordings once in 4 months. Participants may also provide optional Cerebrospinal Fluid (CSF) samples.The participants may also opt into a sub-study if they are interested in genetic testing for ALS causative genes. The sub-study will involve a minimum of 3 visits over a course of 2-3 months. This will include a screening/pre-test genetic counseling visit, a return of genetic results and a post-test counseling visit.


Eligibility

Min Age: 18 Years

Plain Language Summary

Simplified for easier understanding

This clinical trial is studying a new treatment for people with amyotrophic lateral sclerosis. The study is currently recruiting participants at 32 locations.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.


Locations(32)

University of Alabama Birmingham

Birmingham, Alabama, United States

Barrow Neurological Institute

Phoenix, Arizona, United States

University of California San Diego

La Jolla, California, United States

University of California Irvine

Orange, California, United States

University of California, San Francisco

San Francisco, California, United States

University of Colorado Anschutz Medical Campus

Aurora, Colorado, United States

Hospital for Special Care

New Britain, Connecticut, United States

Georgetown University

Washington D.C., District of Columbia, United States

Mayo Clinic

Jacksonville, Florida, United States

Saint Alphonsus Regional Medical Center

Boise, Idaho, United States

Northwestern University

Chicago, Illinois, United States

Indiana University

Indianapolis, Indiana, United States

John Hopkins University

Baltimore, Maryland, United States

Nih/Ninds

Bethesda, Maryland, United States

Massachusetts General Brigham

Boston, Massachusetts, United States

University of Michigan

Ann Arbor, Michigan, United States

Henry Ford Health

Detroit, Michigan, United States

University of Minnesota

Minneapolis, Minnesota, United States

Washington University

St Louis, Missouri, United States

University of Nebraska Medical Center

Omaha, Nebraska, United States

Dartmouth Hitchcock Medical Center

Lebanon, New Hampshire, United States

Columbia University

New York, New York, United States

Duke University

Durham, North Carolina, United States

Ohio State University

Columbus, Ohio, United States

Providence ALS Center

Portland, Oregon, United States

Penn State Health

Hershey, Pennsylvania, United States

Temple University

Philadelphia, Pennsylvania, United States

Texas Neurology

Dallas, Texas, United States

University of Utah

Salt Lake City, Utah, United States

Virginia Commonwealth University

Richmond, Virginia, United States

University of Washington

Seattle, Washington, United States

CHALS-CCT, University of Puerto Rico, Medical Sciences Campus

San Juan, Puerto Rico, Puerto Rico

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT06581861


Related Trials